A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.
News|Articles|June 11, 2026
Advancing the Field: Stem Cell Therapies and the Future of Parkinson Disease Treatment
Author(s)Marco Meglio
Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.
Advertisement
Advertisement
In a recently launched special NeurologyLive® Roundtable Discussion developed in collaboration with the International Society for Stem Cell Research (ISSCR), two leading Parkinson disease experts explored the rapidly advancing field of stem cell medicine and its potential role in treating Parkinson disease.
Related to this article
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
Emerging therapies for muscular dystrophy are targeting a range of disease mechanisms, from RNA-based approaches and muscle-directed delivery to cell therapy and DUX4 suppression.
In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.
Advertisement
Advertisement